JR Rahn is becoming sole CEO for MindMed Inc. in what the company describes as its "MindMed 2.0 leadership team".
JR Rahn is becoming sole CEO for MindMed Inc. in what the company describes as its "MindMed 2.0 leadership team".
Psychedelic Stock Watch examines the Road to Legalization for psychedelic drugs. Part 1: cannabis vs psychedelics.
Mydecine applies for its own NASDAQ listing.
PSYK, the first psychedelics ETF, commences trading today on Canada's Neo Exchange.
Mind Cure announces plans to roll out a line of pre- and post-treatment adaptogen supplements.
Field Trip continues its U.S. expansion with opening of a new clinic in Atlanta.
It's not just how much money that is being raised by psychedelic drug companies. It's HOW they are doing it.
Psyched Wellness increases its bought deal offering from CAD$3 million to CAD$5.5 million.
As trading in psychedelic stocks begins to heat up (again), the emerging psychedelic drug industry is growing rapidly -- vertically and horizontally.
Psyched Wellness announces a CAD$3 million bought deal with units priced at CAD$0.31.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now